in vivo News and Research

RSS

CAR therapy shows potential for advancing treatment of patients with ALL and CLL

Novartis is highlighting new research from members of the faculty at the University of Pennsylvania’s Perelman School of Medicine on the investigational chimeric antigen receptor therapy, CTL019. Several studies being presented at the American Society of Hematology annual meeting add to the scientific understanding of CTL019 in the treatment of acute lymphoblastic leukemia and chronic lymphocytic leukemia and build on earlier research findings.

9 Dec 2013

‘Flesh-eating’ disease treatments: an interview with Dr. John Crew, Seton Medical Center

Untreated, the mortality probably exceeds 70%. Flesh eating is a description of Toxic Inflammatory Cellulitis which usually starts by bacterial subcutaneous infection followed by freezing in phase II healing which is inflammatory.

9 Dec 2013

Researchers one step closer to development of drug-eluting contact lens for glaucoma treatment

For nearly half a century, contact lenses have been proposed as a means of ocular drug delivery that may someday replace eye drops, but achieving controlled drug release has been a significant challenge. Researchers at Massachusetts Eye and Ear/Harvard Medical School Department of Ophthalmology, Boston Children's Hospital, and the Massachusetts Institute of Technology are one step closer to an eye drop-free reality with the development of a drug-eluting contact lens designed for prolonged delivery of latanoprost, a common drug used for the treatment of glaucoma, the leading cause of irreversible blindness worldwide.

9 Dec 2013

UC Santa Barbara extends research contract with Army Research Laboratory

UC Santa Barbara's Institute for Collaborative Biotechnologies has received an extension of its contract with the U.S. Army Research Laboratory-Army Research Office, providing an additional $48 million over three years to support research that is inspired by biological systems. The continuation in ICB funding speaks to the success of a decade of fundamental research in the areas of biotechnology, chemistry, engineering, physics, materials science, computer science, neuroscience and medicine.

9 Dec 2013

Study provides possible therapeutic strategy for Alzheimer's disease via progesterone

Steroid hormones and their metabolites within the central nervous system are commonly defined as neuroactive steroids or neurosteroids. Although neuroactive steroids have been shown to improve learning and memory ability and protect against amyloid beta peptide-induced neurotoxicity, changes in their level during Alzheimer's disease and their role in Aβ-mediated cognitive impairment remain elusive given the limitation in sample sizes and analysis methods.

8 Dec 2013

New study provides novel stem cell based, tissue engineered construct which can repair damaged bone

Researchers at the Department of Orthopaedics, of the Second Affiliated Hospital of Xi'an Jiaotong University Health Science Center, led by Dr. Kunzheng Wang and Dr. Pei Yang have developed a novel biomimetic tissue engineered bone graft based on rabbit adipose derived stem cells (rASCs), collagen I and a porous beta-tricalcium phosphate (β-TCP) scaffold.

5 Dec 2013

Blocking Cdh1 protein could accelerate development of new therapies targeting cancer

The laboratory of Marcos Malumbres, who is head of the Spanish National Cancer Research Centre's (CNIO) Cell Division & Cancer Group, working alongside Isabel Fari-as' team from the University of Valencia, shows, in a study published today in the journal Nature Communications, how in mice the elimination of the Cdh1 protein -a sub-unit of the APC/C complex, involved in the control of cell division-prevents cellular proliferation of rapidly dividing cells.

5 Dec 2013

Research findings pave new ways to treat gastrointestinal disorders

For those living with gastrointestinal disorders, such as ulcers or Crohn's disease, treatment often means quelling uncomfortable symptoms through medications or dietary changes. But what if one day treatment meant doing away with the old gut for a new gut free of inflamed or diseased tissues?

4 Dec 2013

Gladstone scientist devise new molecular sensor that can detect MS at earliest stages

For some, the disease multiple sclerosis attacks its victims slowly and progressively over a period of many years. For others, it strikes without warning in fits and starts. But all patients share one thing in common: the disease had long been present in their nervous systems, hiding under the radar from even the most sophisticated detection methods. But now, scientists at the Gladstone Institutes have devised a new molecular sensor that can detect MS at its earliest stages-even before the onset of physical signs.

3 Dec 2013

New finding links obesity and high-fat, high-sugar diets with changes in inflammatory status

Scientists have moved a step closer to an "obesity drug" that may block the effects of diets high in sugar and fats. In a new research report published in the December 2013 issue of The FASEB Journal, scientists show that there is an abnormal amount of an inflammatory protein called PAR2 in the abdominal fat tissue of overweight and obese humans and rats.

3 Dec 2013

Cyclin D1 protein controls cell cycle progression, microRNA biogenesis in breast cancer

Cyclin D1, a protein that helps push a replicating cell through the cell cycle also mediates the processing and generation of mature microRNA, according to new research publishing November 29 in Nature Communications. The research suggests that a protein strongly implicated in human cancer also governs the non-protein-coding genome. The non-coding genome, previously referred to as junk DNA, makes up most of the human genome, and unlike the coding genome, varies greatly between species.

29 Nov 2013

Patrys to present data from PAT-SM6 Phase I/IIa trial in multiple myeloma at ASH conference

Patrys Limited (ASX: PAB), a clinical stage biotechnology company has announced that updated results from its PAT-SM6 Phase I/IIa clinical trial in multiple myeloma will be presented at the 55th American Society of Hematology Annual Meeting in New Orleans, LA on 7- 10 December 2013.

29 Nov 2013

Data from Patrys' PAT-SM6 Phase I/IIa trial in multiple myeloma to be presented at ASH Annual Meeting

Patrys Limited, a clinical stage biotechnology company has announced that updated results from its PAT-SM6 Phase I/IIa clinical trial in multiple myeloma will be presented at the 55th American Society of Hematology Annual Meeting in New Orleans, LA on 7- 10 December 2013.

29 Nov 2013

Study uncovers mechanisms that allow stem cells to keep dividing in perpetuity

The blood stem cells that live in bone marrow are at the top of a complex family tree. Such stem cells split and divide down various pathways that ultimately produce red cells, white cells and platelets. These "daughter" cells must be produced at a rate of about one million per second to constantly replenish the body's blood supply.

27 Nov 2013

Inhibition of parvalbumin-expressing prefrontal interneurons triggers fear behaviours

Using an approach combining in vivo recordings and optogenetic manipulations in mice, the researchers succeeded in showing that the inhibition of parvalbumin-expressing prefrontal interneurons triggers a chain reaction resulting in fear behaviour. Conversely, activation of these parvalbumin interneurons significantly reduces fear responses in rodents.

22 Nov 2013

Covagen, TRL expand research collaboration to generate bispecific FynomAb

Covagen and Tanabe Research Laboratories U.S.A, Inc., a fully owned subsidiary of Mitsubishi Tanabe Pharma Corporation, today announced that they expanded their strategic research collaboration. MTPC and TRL have nominated a first bispecific FynomAb for formal preclinical development which triggered an undisclosed milestone payment. MTPC and TRL also exercised an option for a second bispecific FynomAb program based on the parties' research and licensing agreement signed in October 2012.

21 Nov 2013

Using radiation models to improve cancer therapies: an interview with Adrian Treverton, COO of Xstrahl and Jean-Pierre Wery, President of Crown Bioscience

What we are trying to do is take a cancer model like the PDX model (patient-derived tumor xenograft), which is a human-derived cancer growing in an in vivo model and apply radiation to that model.

From Xstrahl 20 Nov 2013

Medix Biochemica to launch antibody production services for IVD assays at MEDICA 2013

Medix Biochemica, producer of monoclonal antibodies for the global IVD industry and diagnostic rapid tests, is presenting its MedixMAB by Design and MedixMAB Manufacturing antibody production services to the European market at MEDICA 2013, Dusseldorf, Germany, 20-23 November, Hall 3, Stand F44.

14 Nov 2013

Acquired resistance to cancer therapies: an interview with Dr Rajendra Kumari, Chief Scientific Officer at PRECOS

Cancer can be treated by a number of different ways depending on the location, grade and stage of tumour. A patient's age, medical history and lifestyle will also be taken into consideration and a combination of treatments will also be adopted to provide maximum effect.

14 Nov 2013

Promethera Biosciences completes patient enrolment for first clinical trial of HepaStem

Promethera Biosciences, a Belgian biotechnology company developing Promethera HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, announces today the completion of patient enrolment for its first clinical trial.

12 Nov 2013

in vivo News and Research

CAR therapy shows potential for advancing treatment of patients with ALL and CLL

‘Flesh-eating’ disease treatments: an interview with Dr. John Crew, Seton Medical Center

Researchers one step closer to development of drug-eluting contact lens for glaucoma treatment

UC Santa Barbara extends research contract with Army Research Laboratory

Study provides possible therapeutic strategy for Alzheimer's disease via progesterone

New study provides novel stem cell based, tissue engineered construct which can repair damaged bone

Blocking Cdh1 protein could accelerate development of new therapies targeting cancer

Research findings pave new ways to treat gastrointestinal disorders

Gladstone scientist devise new molecular sensor that can detect MS at earliest stages

New finding links obesity and high-fat, high-sugar diets with changes in inflammatory status

Cyclin D1 protein controls cell cycle progression, microRNA biogenesis in breast cancer

Patrys to present data from PAT-SM6 Phase I/IIa trial in multiple myeloma at ASH conference

Data from Patrys' PAT-SM6 Phase I/IIa trial in multiple myeloma to be presented at ASH Annual Meeting

Study uncovers mechanisms that allow stem cells to keep dividing in perpetuity

Inhibition of parvalbumin-expressing prefrontal interneurons triggers fear behaviours

Covagen, TRL expand research collaboration to generate bispecific FynomAb

Using radiation models to improve cancer therapies: an interview with Adrian Treverton, COO of Xstrahl and Jean-Pierre Wery, President of Crown Bioscience

Medix Biochemica to launch antibody production services for IVD assays at MEDICA 2013

Acquired resistance to cancer therapies: an interview with Dr Rajendra Kumari, Chief Scientific Officer at PRECOS

Promethera Biosciences completes patient enrolment for first clinical trial of HepaStem

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News